Chosa Oncology (CHOSA) Q2 2024 earnings summary

Executive summary

• Maintained strategic momentum with increased recognition for cisplatin-DRP technology among global oncology leaders, focusing on lung, breast, gynecological, and urological cancers.

• Ongoing discussions with potential partners and stakeholders to secure licensing, partnerships, and commercial agreements.

• Recent financing rounds have provided stability to pursue long-term objectives and establish CHOSA as a reliable industry partner.

Financial highlights

• Q2 2024 result after financial items: -1,950 TSEK (improved from -3,471 TSEK in Q2 2023).

• Earnings per share: -0.32 SEK (-0.30 SEK in Q2 2023).

• Cash and cash equivalents as of June 30, 2024: 11,136 TSEK (2,939 TSEK as of June 30, 2023).

• Equity at period end: 19,813 TSEK (20,156 TSEK in Q2 2023).

• No operating revenue; other operating income was 0 TSEK.

Outlook and guidance

• Optimism for future growth, driven by positive feedback from key opinion leaders and ongoing strategic partnerships.

• Focus remains on licensing, sales, and partnerships for LiPlaCis and DRP technologies.